Pharmacological action of
Enrofloxacin, which is part of the preparation, belongs to the group of fluoroquinolones, has a wide spectrum of antibacterial and antimycoplasmic effects, inhibits the growth and development of gram-positive bacteria, such as bacteria. salmonella, pasteurell, staphylococci, streptococci, clostridia, pseudomonads, bordetellas, campylobacteria, corynebacteria, protea, as well as mycoplasmas. The mechanism of action of enrofloxacin is to inhibit the activity of the gyrase enzyme, which affects the replication of the DNA helix in the nucleus of a bacterial cell. With parenteral administration of the drug, enrofloxacin is well and quickly absorbed from the injection site and penetrates into all organs and tissues of the body. The maximum concentration of enrofloxacin in the blood is reached after 20 to 40 minutes, the therapeutic concentration remains for 24 hours after administration of the drug. Baytril 2.5% injection for the degree of exposure to the body refers to moderately hazardous substances, at recommended doses it is well tolerated by animals, does not have embryotoxic, teratogenic and hepatotoxic effects. Enrofloxacin is excreted from the body mainly unchanged, partially metabolized to ciprofloxacin and excreted in urine and feces.
Assign to dogs and cats for therapeutic purposes in diseases of the respiratory system, gastrointestinal tract, genitourinary system, septicemia, colibacteriosis, salmonellosis, streptococcosis and other diseases caused by microorganisms sensitive to fluoroquinol viral diseases.
Hypersensitivity to enrofloxacin and other quinolones. It is forbidden to prescribe to females during pregnancy and lactation, with significant violations of the development of cartilage, lesions of the nervous system, accompanied by convulsions, as well as the allocation of microorganisms resistant to fluoroquinolones from a sick animal. The simultaneous use of Baytril with chloramphenicol, macrolides, tetracyclines, theophylline and non-steroidal anti-inflammatory drugs is not allowed.
25 ml of enrofloxacin and auxiliary components: potassium hydroxide, n-butanol, water for injection are contained in 1 ml of injection solution.
In some cases, a short-term violation of the function of the gastrointestinal tract is possible. Redness may occur at the injection point, disappearing spontaneously.